Foresite Capital Management V, LLC insider trades: Latigo Biotherapeutics (LTGO) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Foresite Capital Management V, LLC reports to the SEC
and 4 more companies
Open-market buys and sales
15 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | LTGO | ↑ Buy | 140,000 | $18.00 | $2.5M | Indirect | Aug 10, 2026 (0d) |
| Feb 4, 2026 | EIKN | ↑ Buy | 55,555 | $18.00 | $1000K | Indirect | Feb 6, 2026 (2d) |
| Jan 8, 2026 | ALMS | ↑ Buy | 411,764 | $17.00 | $7.0M | Indirect | Jan 12, 2026 (4d) |
| Nov 21, 2025 | ALMS | ↑ Buy | 72,212 | $7.38 | $533K | Indirect | Nov 25, 2025 (4d) |
| Nov 19, 2025 | ALMS | ↑ Buy | 507,874 | $6.09 | $3.1M | Indirect | Nov 19, 2025 (0d) |
| May 6, 2025 | ALMS | ↑ Buy | 45,000 | $4.50 | $202K | Indirect | May 6, 2025 (0d) |
| Jul 1, 2024 | ALMS | ↑ Buy | 2,500,000 | $16.00 | $40.0M | Indirect | Jul 3, 2024 (2d) |
| Jul 17, 2023 | THRX | ↑ Buy | 700,000 | $2.97 | $2.1M | Indirect | Jul 19, 2023 (2d) |
| May 8, 2023 | KNTE | ↑ Buy | 1,780,000 | $2.80 | $5.0M | Indirect | May 10, 2023 (2d) |
| Apr 5, 2023 | PRDS | ↑ Buy | 773,952 | $1.50 | $1.2M | Indirect | Apr 6, 2023 (1d) |
| Dec 29, 2022 | THRX | ↑ Buy | 500,000 | $5.00 | $2.5M | Indirect | Jan 3, 2023 (5d) |
| Dec 1, 2022 | PRDS | ↑ Buy | 637,420 | $0.85 | $542K | Indirect | Dec 5, 2022 (4d) |
| Dec 22, 2021 | PRDS | ↑ Buy | 325,000 | $10.00 | $3.3M | Indirect | Dec 23, 2021 (1d) |
| Feb 19, 2021 | FSII | ↑ Buy | 602,500 | $10.00 | $6.0M | Direct | Feb 23, 2021 (4d) |
| Aug 14, 2020 | FSDC | ↑ Buy | 441,500 | $10.00 | $4.4M | Direct | Oct 19, 2020 (66d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LTGO insiders
Open-market trades in the last 12 months
About Foresite Capital Management V, LLC's insider trades
Foresite Capital Management V, LLC is a 10% owner of Latigo Biotherapeutics (LTGO). Since Aug 14, 2020, it has reported 15 open-market purchases worth $79.3M and no sales on SEC Form 4. In the last 12 months: 5 buys ($14.1M).
Its filings also include conversions (6 filings), other transactions (4 filings), grants and awards (3 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LTGO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.